Aptivus achieves SVR in treatment-experienced children

At the 2008 International AIDS Conference, in Mexico City, Boehringer Ingelheim presented new 100-week data showing that Aptivus (tipranavir) enabled treatment-experienced children to achieve sustained virologic and immunologic responses and was a well-tolerated antiretroviral therapy.

According to the German drug major, these results build on the positive 48-week data submitted to US regulators for the recent approval of the Aptivus pediatric oral solution and pediatric indication, which is also currently being reviewed by the European regulators.

This two-year follow-up data evaluated tipranavir co-administered with low-dose ritonavir (Aptivus/r) in 78 treatment-experienced children. Those completing the original 48-week trial were given the choice of continuing their therapy for an extension of the trial. Over half of younger children in the trial achieved sustained virologic response and the oral solution continued to be well tolerated over the 100 weeks.